Equities

Champions Oncology Inc

Champions Oncology Inc

Actions
Health CareHealth Care Providers
  • Price (USD)4.76
  • Today's Change0.06 / 1.28%
  • Shares traded1.87k
  • 1 Year change-2.06%
  • Beta0.4134
Data delayed at least 15 minutes, as of May 20 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.

  • Revenue in USD (TTM)49.22m
  • Net income in USD-9.73m
  • Incorporated1985
  • Employees230.00
  • Location
    Champions Oncology IncSUITE 619, 855 N. WOLFE STREETBALTIMORE 21205United StatesUSA
  • Phone+1 (410) 369-0365
  • Fax+1 (302) 636-5454
  • Websitehttps://championsoncology.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ocean Biomedical Holdings Inc0.00-45.58m60.98m9.00---------1.40-1.400.00-0.0642------0.00-----------------------------612.50------
Earth Science Tech Inc5.98m330.94k61.08m8.00202.0828.30115.4110.210.0010.0010.01950.00693.1611.41106.07747,970.0017.50-224.8442.70--62.2937.795.53-333.580.386-0.38990.1023--243.77-36.31-111.95------
Kronos Bio Inc7.59m-116.39m61.30m61.00--0.4475--8.08-2.00-2.000.13012.280.0322----122,371.00-49.32-35.47-54.43-37.14-----1,534.11-7,975.76----0.00------15.41---8.78--
Turnstone Biologics Corp0.00-74.92m61.52m82.00--0.7689-----3.53-3.530.003.460.00----0.00-80.25---94.45--------------0.00---73.66---78.05------
Eagle Pharmaceuticals Inc257.55m11.95m61.82m134.005.220.24731.890.240.9110.91119.5919.250.65491.552.561,922,022.003.046.374.047.9869.8471.864.647.851.673.550.21780.0084.565.99513.14-8.42-49.05--
RetinalGenix Technologies Inc0.00-2.09m62.25m0.00---------0.1205-0.12050.00-0.07970.00-------929,284.40-9,163.75---------------543.50--------46.58------
Avrobio Inc0.0030.31m62.40m13.002.010.70222.04--0.69030.69030.001.980.00----0.0034.57-45.2238.47-49.14------------0.00------111.48---66.27--
Protara Therapeutics Inc0.00-42.47m63.62m26.00--0.6049-----3.74-3.740.005.110.00----0.00-48.67-37.02-52.23-38.29------------0.00------38.71---17.67--
Mural Oncology PLC-100.00bn-100.00bn63.63m117.00--0.2708----------13.88----------------------------0.00-------9.29------
VolitionRX Ltd797.03k-34.91m63.77m110.00------80.02-0.4603-0.46030.0104-0.19010.0425--6.327,245.73-188.25-111.92---196.20-----4,425.95-10,793.31---173.85----153.04---16.68--29.13--
Champions Oncology Inc49.22m-9.73m63.89m230.00------1.30-0.7183-0.71833.64-0.15141.56--6.17214,017.40-30.91-5.40-96.45-11.8840.0947.96-19.76-3.09--------9.6921.63-1,073.54--18.50--
Bioqual Inc62.86m957.02k64.85m108.0067.761.6718.491.031.071.0770.2843.411.04--2.99--1.598.141.809.5214.1319.361.527.13----0.0021.43-5.2711.79-84.12-25.261.6010.76
Lantern Pharma Inc0.00-17.53m64.88m21.00--1.81-----1.62-1.620.003.320.00----0.00-36.82-28.83-39.63-30.17------------0.00-------11.93------
Immix Biopharma Inc0.00-18.21m65.22m14.00--2.34-----0.9263-0.92630.001.060.00----0.00-77.50---90.46--------------0.00-------87.44------
Celularity Inc14.79m-181.41m65.35m225.00--1.92--4.42-10.51-10.510.83761.560.04982.292.0365,724.45-61.05---82.37--21.19---1,226.72--0.136618.400.5365---15.75--114.18------
enVVeno Medical Corp0.00-22.12m66.52m31.00--1.57-----1.70-1.700.003.180.00----0.00-54.31-58.43-56.14-62.76-------260,799.30----0.00------4.67--21.58--
Data as of May 20 2024. Currency figures normalised to Champions Oncology Inc's reporting currency: US Dollar USD

Institutional shareholders

17.55%Per cent of shares held by top holders
HolderShares% Held
West Elk Capital LLCas of 25 Aug 20231.09m8.04%
Tocqueville Asset Management LPas of 31 Mar 2024684.63k5.04%
Renaissance Technologies LLCas of 31 Mar 2024124.69k0.92%
BlackRock Fund Advisorsas of 31 Mar 2024113.87k0.84%
The Vanguard Group, Inc.as of 31 Mar 202483.51k0.61%
Essex Investment Management Co. LLCas of 31 Mar 202477.20k0.57%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 202469.30k0.51%
Geode Capital Management LLCas of 31 Mar 202462.11k0.46%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202440.70k0.30%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202436.11k0.27%
More ▼
Data from 08 Oct 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.